Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $53.04 in the prior trading day, Cytokinetics Inc (NASDAQ: CYTK) closed at $52.40, down -1.21%. In other words, the price has decreased by -$1.21 from its previous closing price. On the day, 0.95 million shares were traded. CYTK stock price reached its highest trading level at $53.78 during the session, while it also had its lowest trading level at $52.09.
Ratios:
Our goal is to gain a better understanding of CYTK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 7.28 whereas as Long-Term Debt/Eq ratio is at 7.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 13, 2024, Downgraded its rating to Neutral and sets its target price to $60 from $85 previously.
On January 24, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $61 to $92.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 05, 2024, whereas the target price for the stock was revised from $60 to $90.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’24 when Malik Fady Ibraham sold 7,300 shares for $54.19 per share. The transaction valued at 395,554 led to the insider holds 116,920 shares of the business.
FADY MALIK bought 7,300 shares of CYTK for $395,578 on Oct 15 ’24. On Oct 09 ’24, another insider, Blum Robert I, who serves as the President & CEO of the company, sold 5,000 shares for $55.61 each. As a result, the insider received 278,050 and left with 397,456 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6240683008 and an Enterprise Value of 5898762752. For the stock, the TTM Price-to-Sale (P/S) ratio is 1969.77 while its Price-to-Book (P/B) ratio in mrq is 56.73. Its current Enterprise Value per Revenue stands at 1882.183 whereas that against EBITDA is -11.961.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $30.37. The 50-Day Moving Average of the stock is -4.56%, while the 200-Day Moving Average is calculated to be -16.19%.
Shares Statistics:
The stock has traded on average 1.21M shares per day over the past 3-months and 997460 shares per day over the last 10 days, according to various share statistics. A total of 117.66M shares are outstanding, with a floating share count of 113.75M. Insiders hold about 3.33% of the company’s shares, while institutions hold 113.82% stake in the company. Shares short for CYTK as of 1727654400 were 17322576 with a Short Ratio of 14.31, compared to 1724976000 on 18207015. Therefore, it implies a Short% of Shares Outstanding of 17322576 and a Short% of Float of 22.5.
